RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer

Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer

(2021) David M. O'Malley et al.   GYNECOLOGIC ONCOLOGY

Novel Therapeutics for Recurrent Cervical Cancer: Moving Towards Personalized Therapy

(2020) Alexander C. Cohen et al.   DRUGS

Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials

(2020) Omid Kooshkaki et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis

(2020) Jingjie Chen et al.   World Journal of Surgical Oncology

LBA34 Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials

(2020) D.M. O'Malley et al.   ANNALS OF ONCOLOGY

Cervical cancer

(2019) Paul A Cohen et al.   LANCET

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

(2019) Robert M. Samstein et al.   NATURE GENETICS

PD-1/PD-L1 Inhibitors in Cervical Cancer

(2019) Yuncong Liu et al.   Frontiers in Pharmacology

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study

(2019) Hyun Cheol Chung et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination of CTLA-4 and PD-1 blockers for treatment of cancer

(2019) Anand Rotte   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial

(2019) R. Wendel Naumann et al.   JOURNAL OF CLINICAL ONCOLOGY

The prognostic landscape of tumor-infiltrating immune cells in cervical cancer

(2019) Jingnan Wang et al.   BIOMEDICINE & PHARMACOTHERAPY

Targeted therapies in gynaecological cancers

(2019) Shanthini M Crusz et al.   HISTOPATHOLOGY

Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis

(2019) Marc Arbyn et al.   Lancet Global Health

Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody

(2018) Randi B. Gombos et al.   PLoS One

Emerging strategies for combination checkpoint modulators in cancer immunotherapy

(2018) Aleksandra Popovic et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase 1/2 open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation.

(2018) Kathleen N. Moore et al.   JOURNAL OF CLINICAL ONCOLOGY

1158PPhase I/II, open-label, multiple ascending dose trial of AGEN2034, an anti–PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation in advanced cancer and expansion cohorts in subjects with relapsed/refractory cervical cancer

(2018) C Drescher et al.   ANNALS OF ONCOLOGY

Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis

(2018) Cheng Xu et al.   BMJ-British Medical Journal

Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial

(2017) Jean-Sebastien Frenel et al.   JOURNAL OF CLINICAL ONCOLOGY

Integrated genomic and molecular characterization of cervical cancer

(2017)   NATURE

CTLA-4 and PD-1 Pathways

(2016) Elizabeth I. Buchbinder et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review

(2016) Stergios Boussios et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Improved Survival with Bevacizumab in Advanced Cervical Cancer

(2014) Krishnansu S. Tewari et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study

(2009) Bradley J. Monk et al.   JOURNAL OF CLINICAL ONCOLOGY

Papillomaviruses in the causation of human cancers — a brief historical account

(2009) Harald zur Hausen   VIROLOGY